This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA  Topic Collections  • Quality of Life  • Diagnosis  • Alert me on articles by topic  Social Bookmarking   What's this?

The CDC Diabetes Cost-Effectiveness Study Group

JAMA. 1998;280:1757-1763.

Context.— Type 2 diabetes mellitus is a common and serious disease in the United States, but one third of those affected are unaware they have it.

Objective.— To estimate the cost-effectiveness of early detection and treatment of type 2 diabetes.

Design.— A Monte Carlo computer simulation model was developed to estimate the lifetime costs and benefits of 1-time opportunistic screening (ie, performed during routine contact with the medical care system) for type 2 diabetes and to compare them with current clinical practice. Cost-effectiveness was estimated for all persons aged 25 years or older, for age-specific subgroups, and for African Americans. Data were obtained from clinical trials, epidemiologic studies, and population surveys, and a single-payer perspective was assumed. Costs and benefits are discounted at 3% and costs are expressed in 1995 US dollars.

Setting.— Single-payer health care system.

Participants.— Hypothetical cohort of 10,000 persons with newly diagnosed diabetes from the general US population.

Main Outcome Measures.— Cost per additional life-year gained and cost per quality-adjusted life-year (QALY) gained.

Results.— The incremental cost of opportunistic screening among all persons aged 25 years or older is estimated at $236,449 per life-year gained and $56,649 per QALY gained. Screening is more cost-effective among younger people and among African Americans. The benefits of early detection and treatment accrue more from postponement of complications and the resulting improvement in quality of life than from additional life-years.

Conclusions.— Early diagnosis and treatment through opportunistic screening of type 2 diabetes may reduce the lifetime incidence of major microvascular complications and result in gains in both life-years and QALYs. Incremental increases in costs attributable to screening and earlier treatment are incurred but may well be in the range of acceptable cost-effectiveness for US health care systems, especially for younger adults and for some subpopulations (eg, minorities) who are at relatively high risk of developing the major complications of type 2 diabetes. Although current recommendations are that screening begin at age 45 years, these results suggest that screening is more cost-effective at younger ages. The selection of appropriate target populations for screening should consider factors in addition to the prevalence of diabetes.

Members of the CDC Diabetes Cost-Effectiveness Study Group include Michael M. Engelgau, MD, K. M. Venkat Narayan, MD, Theodore J. Thompson, MS, James P. Boyle, PhD, and David F. Williamson, PhD, Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Ga; W. Dana Flanders, MD, MSc, Division of Epidemiology, School of Public Health, Emory University, Atlanta; Diane L. Manninen, PhD, Fred B. Dong, AM, MBA, and Carlyn E. Orians, MA, Battelle Centers for Public Health Research, Seattle, Wash; Erik J. Dasbach, PhD, Merck and Company, Inc, Blue Bell, Pa; Steven M. Teutsch, Merck and Company, Inc, West Point, Pa; Richard Eastman, MD, Division of Diabetes, Endrocrinology, and Metabolic Diseases, National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Md; William H. Herman, MD, Division of Endrocrinology and Metabolism, Department of Medicine, University of Michigan, Ann Arbor; and Thomas J. Songer, PhD, Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pa.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Screening for Type 2 Diabetes
Elizabeth Goyder, Les Irwig, Elton Kessel, Michael M. Engelgau, K. M. Venkat Narayan, David F. Williamson, Theodore J. Thomson, and Fred Dong
JAMA. 1999;281(21):1986-1988.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria
Delea et al.
J. Am. Soc. Nephrol. 2009;20:2205-2213.
ABSTRACT | FULL TEXT  

Tool to Assess Likelihood of Fasting Glucose ImpairmenT (TAG-IT)
Koopman et al.
Ann Fam Med 2008;6:555-561.
ABSTRACT | FULL TEXT  

Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force
Norris et al.
ANN INTERN MED 2008;148:855-868.
ABSTRACT | FULL TEXT  

Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis
Gillies et al.
BMJ 2008;336:1180-1185.
ABSTRACT | FULL TEXT  

Age, BMI, and Race Are Less Important Than Random Plasma Glucose in Identifying Risk of Glucose Intolerance: The Screening for Impaired Glucose Tolerance Study (SIGT 5)
Ziemer et al.
Diabetes Care 2008;31:884-886.
ABSTRACT | FULL TEXT  

Diabetes Epidemiology: Guiding Clinical and Public Health Practice: The Kelly West Award Lecture, 2006
Herman
Diabetes Care 2007;30:1912-1919.
FULL TEXT  

Efficacy and Cost of Postpartum Screening Strategies for Diabetes Among Women With Histories of Gestational Diabetes Mellitus
Kim et al.
Diabetes Care 2007;30:1102-1106.
ABSTRACT | FULL TEXT  

Diabetes: How Are We Diagnosing and Initially Managing It?
O'Connor et al.
Ann Fam Med 2006;4:15-22.
ABSTRACT | FULL TEXT  

Surveillance for isocyanate asthma: a model based cost effectiveness analysis
Wild et al.
Occup. Environ. Med. 2005;62:743-749.
ABSTRACT | FULL TEXT  

Changes in Age at Diagnosis of Type 2 Diabetes Mellitus in the United States, 1988 to 2000
Koopman et al.
Ann Fam Med 2005;3:60-63.
ABSTRACT | FULL TEXT  

Cost-Effectiveness Analysis of Different Screening Procedures for Type 2 Diabetes: The KORA Survey 2000
Icks et al.
Diabetes Care 2004;27:2120-2128.
ABSTRACT | FULL TEXT  

Screening for IGT and diabetes
Tringham and Davies
British Journal of Diabetes & Vascular Disease 2004;4:254-258.
ABSTRACT  

Type 2 Diabetes in the Young: The Evolving Epidemic: The International Diabetes Federation Consensus Workshop
Alberti et al.
Diabetes Care 2004;27:1798-1811.
FULL TEXT  

Primary Prevention of Type 2 Diabetes Mellitus by Lifestyle Intervention: Implications for Health Policy
Centers for Disease Control and Prevention Primary
ANN INTERN MED 2004;140:951-957.
ABSTRACT | FULL TEXT  

Application of Economic Analysis to Diabetes and Diabetes Care
Zhang et al.
ANN INTERN MED 2004;140:972-977.
ABSTRACT | FULL TEXT  

Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis
Hoerger et al.
ANN INTERN MED 2004;140:689-699.
ABSTRACT | FULL TEXT  

Screening for Diabetes: Can We Afford Not To Screen?
Nathan and Herman
ANN INTERN MED 2004;140:756-758.
FULL TEXT  

Type 2 Diabetes in the Young: The evolving epidemic
Bloomgarden
Diabetes Care 2004;27:998-1010.
FULL TEXT  

Prevention or Delay of Type 2 Diabetes
Diabetes Care 2004;27:s47-47.
FULL TEXT  

Archimedes: A trial-validated model of diabetes
Eddy and Schlessinger
Diabetes Care 2003;26:3093-3101.
ABSTRACT | FULL TEXT  

Prevention and Treatment of Type 2 Diabetes Mellitus in Children, With Special Emphasis on American Indian and Alaska Native Children
Gahagan et al.
Pediatrics 2003;112:e328-e328.
ABSTRACT | FULL TEXT  

Pediatricians' Perceptions and Practices Regarding Prevention and Treatment of Type 2 Diabetes Mellitus in Children and Adolescents
Ditmyer et al.
Arch Pediatr Adolesc Med 2003;157:913-918.
ABSTRACT | FULL TEXT  

Predicted Costs and Outcomes From Reduced Vibration Detection in People With Diabetes in the U.S.
Shearer et al.
Diabetes Care 2003;26:2305-2310.
ABSTRACT | FULL TEXT  

Quality of Care for Patients Diagnosed With Diabetes at Screening
Edelman et al.
Diabetes Care 2003;26:367-371.
ABSTRACT | FULL TEXT  

The Prevention or Delay of Type 2 Diabetes
Diabetes Care 2003;26:s62-69.
FULL TEXT  

The Prevention or Delay of Type 2 Diabetes
Clin. Diabetes 2002;20:109-116.
FULL TEXT  

The Prevention or Delay of Type 2 Diabetes
Diabetes Spectr. 2002;15:147-157.
FULL TEXT  

Impact of Diabetes Screening on Quality of Life
Edelman et al.
Diabetes Care 2002;25:1022-1026.
ABSTRACT | FULL TEXT  

Cumulative Risk for Developing End-Stage Renal Disease in the US Population
Kiberd and Clase
J. Am. Soc. Nephrol. 2002;13:1635-1644.
ABSTRACT | FULL TEXT  

Cost-effectiveness of Intensive Glycemic Control, Intensified Hypertension Control, and Serum Cholesterol Level Reduction for Type 2 Diabetes
The CDC Diabetes Cost-effectiveness Group
JAMA 2002;287:2542-2551.
ABSTRACT | FULL TEXT  

The Prevention or Delay of Type 2 Diabetes
American Diabetes Association
Diabetes Care 2002;25:742-749.
FULL TEXT  

Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus
Sacks et al.
Clin. Chem. 2002;48:436-472.
ABSTRACT | FULL TEXT  

Screening for diabetes in general practice
Hagstrom et al.
BMJ 2002;324:425-425.
FULL TEXT  

A Health Economic Model to Assess the Long-Term Effects and Cost-Effectiveness of Orlistat in Obese Type 2 Diabetic Patients
Lamotte et al.
Diabetes Care 2002;25:303-308.
ABSTRACT | FULL TEXT  

Type 2 Diabetes in Older Well-Functioning People: Who Is Undiagnosed?: Data from the Health, Aging, and Body Composition Study
Franse et al.
Diabetes Care 2001;24:2065-2070.
ABSTRACT | FULL TEXT  

Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria
Wareham and Griffin
BMJ 2001;322:986-988.
FULL TEXT  

Subclinical States of Glucose Intolerance and Risk of Death in the U.S.
Saydah et al.
Diabetes Care 2001;24:447-453.
ABSTRACT | FULL TEXT  

Undiagnosed diabetes: Does it matter?
Young and Mustard
CMAJ 2001;164:24-28.
ABSTRACT | FULL TEXT  

Opportunistic Discovery of Occult Disease by Use of Test Panels in New, Symptomatic Primary Care Outpatients: Yield and Cost of Case Finding
Takemura et al.
Clin. Chem. 2000;46:1091-1098.
ABSTRACT | FULL TEXT  

Cost-effectiveness of the Lower Treatment Goal (of JNC VI) for Diabetic Hypertensive Patients
Elliott et al.
Arch Intern Med 2000;160:1277-1283.
ABSTRACT | FULL TEXT  

Glycosylated Hemoglobin as a Diagnostic Test for Type 2 Diabetes Mellitus
Rayburn et al.
JAMA 2000;283:605-607.
FULL TEXT  

Early opportunistic screening was cost effective in young adults with type 2 diabetes
Chang and Henry
Evid. Based Nurs. 1999;2:91-91.
FULL TEXT  

Screening for Type 2 Diabetes
Goyder et al.
JAMA 1999;281:1986-1988.
FULL TEXT  

Screening for Type 2 Diabetes Is Cost-Effective
JWatch Women's Health 1999;1999:5-5.
FULL TEXT